© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Getting access to the new hep C drugs remains an ongoing barrier for too many people, but the drugs keep getting better.
Merck’s investigational hepatitis C treatment grazoprevir/elbasvir cured high rates of the virus among individuals coinfected with HIV.
Individuals who have failed hepatitis C treatment may ultimately achieve a cure if they add Sovaldi (sofosbuvir) to a subsequent treatment reg...
Drinking coffee is linked with reduced liver fibrosis among people with hepatitis B, hepatitis C, and non-alcoholic fatty liver disease.
Sovaldi and velpatasvir, with/without ribavirin, yielded good results among people with various genotypes of HCV and decompensated cirrhosis
Twelve or 16 weeks of Sovaldi (sofosbuvir) and ravidasvir cured high rates of people with genotype 4 of hepatitis C virus in a recent large tr...
8 weeks of Harvoni (ledipasvir/sofosbuvir) and vedroprevir boasted a near-perfect cure rate among those with genotype 1 and advanced liver dis...
Gilead Sciences Sovaldi (sofosbuvir) and velpatasvir posted near-perfect results in curing an array of genotypes of hepatitis C.
Long time health advocate Bill Remak’s reflections on the 2015 AASLD Liver Meeting and hepatitis C advocacy
Those with advanced fibrosis or cirrhosis who are cured of hepatitis C often experience regression of liver damage, improving by at least one...
Daklinza (daclatasvir) and Sovaldi (sofosbuvir) more effectively cures hepatitis C among those coinfected with HIV than does Sovaldi and...
Eight or 12 weeks of AbbVie’s investigational hepatitis C treatments ABT-493 and ABT-530 cured 97 to 100 percent of people with genotype 1.
AbbVie’s investigational hepatitis C treatments ABT-493 and ABT-530 posted mostly high cure rates among people with genotypes 2 and 3.
The high success rate of today’s hepatitis C treatments may keep many people from needing a liver transplant.
A nucleic acid-based polymer called REP 2139, given alone and with interferon, has shown promise treating coinfection with hep B and hep D.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.